406 related articles for article (PubMed ID: 7526902)
1. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
O'Shaughnessy JA; Cowan KH; Nienhuis AW; McDonagh KT; Sorrentino BP; Dunbar CE; Chiang Y; Wilson W; Goldspiel B; Kohler D
Hum Gene Ther; 1994 Jul; 5(7):891-911. PubMed ID: 7526902
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
Cowan KH; Moscow JA; Huang H; Zujewski JA; O'Shaughnessy J; Sorrentino B; Hines K; Carter C; Schneider E; Cusack G; Noone M; Dunbar C; Steinberg S; Wilson W; Goldspiel B; Read EJ; Leitman SF; McDonagh K; Chow C; Abati A; Chiang Y; Chang YN; Gottesman MM; Pastan I; Nienhuis A
Clin Cancer Res; 1999 Jul; 5(7):1619-28. PubMed ID: 10430060
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer.
O'Shaughnessy JA; Cowan KH; Wilson W; Bryant G; Goldspiel B; Gress R; Nienhuis AW; Dunbar C; Sorrentino B; Stewart FM
Hum Gene Ther; 1993 Jun; 4(3):331-54. PubMed ID: 8338880
[No Abstract] [Full Text] [Related]
4. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene.
Hanania EG; Fu S; Zu Z; Hegewisch-Becker S; Korbling M; Hester J; Durett A; Andreeff M; Mechetner E; Holzmayer T
Gene Ther; 1995 Jun; 2(4):285-94. PubMed ID: 7552989
[TBL] [Abstract][Full Text] [Related]
6. Human MDR gene transfer in patients with advanced cancer.
Hesdorffer C; Antman K; Bank A; Fetell M; Mears G; Begg M
Hum Gene Ther; 1994 Sep; 5(9):1151-60. PubMed ID: 7833373
[No Abstract] [Full Text] [Related]
7. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model.
Hanania EG; Deisseroth AB
Cancer Gene Ther; 1994 Mar; 1(1):21-5. PubMed ID: 7621234
[TBL] [Abstract][Full Text] [Related]
8. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Thomson B; Hawkins D; Felgenhauer J; Radich J
Bone Marrow Transplant; 1999 Sep; 24(5):527-33. PubMed ID: 10482938
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
Takahashi S; Aiba K; Ito Y; Hatake K; Nakane M; Kobayashi T; Minowa S; Shibata H; Mitsuhashi J; Tsukahara S; Ishikawa E; Suzuki R; Tsuruo T; Sugimoto Y
Cancer Sci; 2007 Oct; 98(10):1609-16. PubMed ID: 17683514
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.
Hesdorffer C; Ayello J; Ward M; Kaubisch A; Vahdat L; Balmaceda C; Garrett T; Fetell M; Reiss R; Bank A; Antman K
J Clin Oncol; 1998 Jan; 16(1):165-72. PubMed ID: 9440739
[TBL] [Abstract][Full Text] [Related]
13. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Deisseroth AB; Holmes F; Hortobagyi G; Champlin R
Hum Gene Ther; 1996 Feb; 7(3):401-16. PubMed ID: 8835224
[No Abstract] [Full Text] [Related]
14. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
[TBL] [Abstract][Full Text] [Related]
15. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.
Rahman Z; Kavanagh J; Champlin R; Giles R; Hanania E; Fu S; Zu Z; Mehra R; Holmes F; Kudelka A; Claxton D; Verschraegen C; Gajewski J; Andreeff M; Heimfeld S; Berenson R; Ellerson D; Calvert L; Mechetner E; Holzmayer T; Dayne A; Hamer J; Bachier C; Ostrove J; Deisseroth A
Clin Cancer Res; 1998 Nov; 4(11):2717-21. PubMed ID: 9829734
[TBL] [Abstract][Full Text] [Related]
17. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
18. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
19. Influence of interleukin-3, interleukin-6, and stem cell factor on retroviral transduction of rhesus monkey CD34+ hematopoietic progenitor cells measured in vitro and in vivo.
van Beusechem VW; Bart-Baumeister JA; Hoogerbrugge PM; Valerio D
Gene Ther; 1995 Jun; 2(4):245-55. PubMed ID: 7552984
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
